MAXCYTE, INC. — Investor Relations & Filings
MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - MAXCYTE, INC. (0001287098) (Filer) | 2026-03-27 | English | |
| SCHEDULE 13G/A - MAXCYTE, INC. (0001287098) (Subject) | 2026-03-27 | English | |
| SCHEDULE 13G Filing | 2026-02-05 | English | |
| 8-K Filing | 2026-01-12 | English | |
| Major Shareholding Notification 2025 | 2025-11-14 | English | |
| 10-Q | 2025-11-13 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
4 filings
| |||||
| 33065964 | 8-K - MAXCYTE, INC. (0001287098) (Filer) | 2026-03-27 | English | ||
| 33061623 | SCHEDULE 13G/A - MAXCYTE, INC. (0001287098) (Subject) | 2026-03-27 | English | ||
| 28677652 | SCHEDULE 13G Filing | 2026-02-05 | English | ||
| 28677654 | 8-K Filing | 2026-01-12 | English | ||
|
2025
11 filings
| |||||
| 11680606 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 11680607 | 10-Q | 2025-11-13 | English | ||
| 11680611 | 8-K | 2025-11-12 | English | ||
| 11680609 | 8-K | 2025-11-05 | English | ||
| 11680608 | Major Shareholding Notification 2025 | 2025-11-04 | English | ||
| 11680610 | Major Shareholding Notification 2025 | 2025-11-03 | English | ||
| 11680612 | Major Shareholding Notification 2025 | 2025-10-24 | English | ||
| 11680613 | 8-K | 2025-09-22 | English | ||
| 11680614 | Director's Dealing 2025 | 2025-08-27 | English | ||
| 11680615 | FORM S-8 | 2025-08-26 | English | ||
| 11680616 | Director's Dealing 2025 | 2025-08-13 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Atara Biotherapeutics, Inc.
Develops off-the-shelf allogeneic T-cell immunotherapies fo…
|
ATRA | US | Professional, scientific and te… |
|
ATUM CO., LTD.
An integrated biologics development partner offering servic…
|
355690 | KR | Professional, scientific and te… |
|
AUREKA LIMITED
Accelerates drug discovery and development using AI and com…
|
AKA | AU | Professional, scientific and te… |
|
Avalo Therapeutics, Inc.
Clinical-stage biotech developing treatments for immune-med…
|
AVTX | US | Professional, scientific and te… |
|
Azenta, Inc.
Offers sample management, storage, and multiomics solutions…
|
AZTA | US | Professional, scientific and te… |
|
Baijin Life Science Holdings Limited
An investment holding company operating in biopharmaceutica…
|
1466 | HK | Professional, scientific and te… |
|
BCAL DIAGNOSTICS LIMITED
Developing a non-invasive blood test for early breast cance…
|
BDX | AU | Professional, scientific and te… |
|
BEBETTER MED INC.
Develops small molecule therapeutics for oncology, metaboli…
|
688759 | CN | Professional, scientific and te… |
|
Beijing Sun-Novo Pharmaceutical Research Co.,Ltd.
Integrated CRO providing full-spectrum R&D from drug discov…
|
688621 | CN | Professional, scientific and te… |
|
BenevolentAI
Applies artificial intelligence to accelerate drug discover…
|
BAI | LU | Professional, scientific and te… |
MAXCYTE, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/10520/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=10520 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=10520 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=10520 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 10520}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for MAXCYTE, INC. (id: 10520)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.